Ongoing research promotes efficiency and safety with these therapies, primarily as concerns initially arose due to the tumor's immunosuppressive environment. Recently, studies have even begun researching dual-targeting CAR T-cells combined with bispecific antibodies, showing signs of rapid tumor regression in clinical trials. However, this still poses challenges when maintaining long-term efficiency . In another study, the use of CARv3-TEAM-E T-cells for targeting EGFRvIII and wild-type EGFR was studied and resulted in significant but temporary tumor reduction . Although CAR T-cells prove to show remarkably rapid tumor regression, research is now exploring avenues to prolong the therapy's persistence and effectiveness through various methods, such as serial infusions and preconditioning with chemotherapy . This study presents some limitations, as the accuracy of the results depends on the algorithms and models used. When using an inaccurate model, there is the possibility of creating false positives. For further validation, processes such as SPR and/or ITC should be performed to confirm that the ligands are binding to the protein. In addition, a binding analysis can be conducted to gain a more in-depth view of the specific amino acids involved in the binding process. In the future, it was recognized that it would be beneficial to automate the process to streamline evaluating the peptides, increasing efficiency and testing more in less time.